Navigation Links
Labopharm amends debt facility agreement with Hercules
Date:6/25/2009

structuring of the Canadian asset-backed commercial paper, which amount the Company can, under certain conditions, repay at maturity by delivering the notes to the bank.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, major European markets, and Australia, among others. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
2. Labopharm Reports Results for First Quarter Fiscal 2009
3. Labopharm announces details for first quarter results conference call and annual meeting
4. Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation
5. Labopharm to present at Cowen 29th Annual Health Care Conference
6. Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008
7. Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET)
8. Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
9. Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain
10. Labopharm to host webcast presentation on novel trazodone formulation - tomorrow (Dec.16/08) at 10:00 a.m. ET
11. Labopharm Comments on Recent Trading Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 “ LiveSchool ” was featured ... takes a look at the latest and coolest applications ... Toohey, the host of AppWatch and technology expert, conducted ... application allows teachers to reward students with good behavior. ... especially in the classroom. And the good people ...
(Date:5/4/2015)... Jacksonville, Fla. (PRWEB) May 04, 2015 ... American Heart Association/American Stroke Association’s Get With The ... the Target: Stroke Honor Roll. The award recognizes ... stroke patients receive the most appropriate treatment according ... latest scientific evidence. , To receive the Gold ...
(Date:5/4/2015)... Ticket Down is a reputable source for ... . While the World Cup is the most known ... years, the International Champions Cup is one of the biggest ... attendance record for soccer in the United States set when ... the University of Michigan. This year, the defending champion Manchester ...
(Date:5/4/2015)... Ticket Down is a reputable source for authentic Paul ... South Carolina. Fans of Paul McCartney have to be ... originally kicked off in 2013. The most visited continent of ... performer recently announced that he would be adding additional dates ... in Charlottesville, VA at John Paul Jones Arena on ...
(Date:5/4/2015)... NY (PRWEB) May 04, 2015 Sheltering ... Learning Center from Hale House. The Mother Hale Learning ... high-quality, affordable Early Childhood Education. Sheltering Arms will begin ... continue to be served by the center. , Opened ... children ages six weeks to five years, many of ...
Breaking Medicine News(10 mins):Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 2Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 3Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 4Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2Health News:Sheltering Arms Acquires the Mother Hale Learning Center 2
... , TUESDAY, Nov. 16 (HealthDay News) -- Antibiotics may help ... drugs also come with the risk of side effects, concludes ... and 10 percent of children experience side effects, such as ... "If you have 100 healthy children with an ...
... advanced liver cancer with the agent doxorubicin (routinely used ... sorafenib resulted in greater overall survival and progression-free survival, ... according to a study in the November 17 issue ... is the sixth most common malignancy worldwide, with approximately ...
... Mich. Transforming vacant urban lots into farms and ... of their fruits and vegetables. As city officials ... study indicates that a combination of urban farms, community ... to extend the growing season could supply local ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, ... open clogged arteries in addition to standard drug therapy ... in diabetics with heart disease, new research finds. ... Association,s annual meeting in Chicago, is part of a ...
... Nov. 16 (HealthDay News) -- Implantable cardioverter defibrillators (ICDs) that ... for necessary upgrades -- can be safely used again for ... on a small study of 31 patients in India who ... from other patients. The study, led by Dr. Behzad ...
... Researchers have found that many cystic fibrosis (CF) patients in Canada ... , which can increase the risk of death or the need ... strain, first identified in the U.K., is yet common among ... CF patients in Ontario and found that 102 of them were ...
Cached Medicine News:Health News:Antibiotics a Mixed Bag for Kids' Ear Infections: Analysis 2Health News:Antibiotics a Mixed Bag for Kids' Ear Infections: Analysis 3Health News:Combination therapy improves survival time for patients with advanced liver cancer 2Health News:Detroit's urban farms could provide a majority of produce for local residents 2Health News:Adding Surgery to Meds May Help Diabetics With Heart Disease 2Health News:Old Defibrillators Safe for Re-use 2Health News:Severe Bacterial Strain Found in Cystic Fibrosis Patients in Canada 2
(Date:5/4/2015)... TAIPEI , May 4, 2015 ... partner, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... BAX ) jointly announced that Baxter has ... European Medicines Agency (EMA) for MM-398 (irinotecan liposome ... metastatic adenocarcinoma of the pancreas who have been ...
(Date:5/4/2015)... DOYLESTOWN, Pa. , May 4, 2015  Makindus, ... announced today that the European Medicines Agency (EMA) has ... for the treatment of Stargardt,s Disease. "We ... for MI-100 to treat Stargardt,s disease in place for ... our development program in the United States ...
(Date:5/4/2015)... Bayer HealthCare (Bayer) has entered into an ... ISIS ) on ISIS-FXI Rx, an antisense investigational ... Under the agreement Bayer will further develop and commercialize ... need. As part of the clinical development program, Bayer ... in an appropriate patient community. "Bayer ...
Breaking Medicine Technology:PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3European Medicines Agency (EMA) Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
... Delcath Systems, Inc. (Nasdaq: DCTH ) announced ... discuss its recent corporate developments and update its progress on ... President and Chief Executive Officer will host the call. ... 800-322-5044 for domestic participants and 617-614-4927 for international participants, both ...
... 2011 CVS Caremark Corporation (NYSE: CVS ... present at two investor conferences in the month of ... CVS Caremark, will be making a presentation to investors ... on Thursday, November 10th, at approximately 10:00 a.m. MST ...
Cached Medicine Technology:Delcath Systems to Report Third Quarter Progress and Conduct Conference Call 2Delcath Systems to Report Third Quarter Progress and Conduct Conference Call 3CVS Caremark to Present at Upcoming Conferences 2
... proven electrophoretic transfer apparatus incorporating state-of-the-art plate ... Its design allows for a very close ... with a low voltage power source such ... field in volts/cm. The result is exceptionally ...
... RNA from agarose gels to hybridization membranes ... speed and efficiency of transfer by allowing ... ,Part of an integrated system allowing electrophoresis, ... 2.5 hours, versus 29 hours required for ...
... Transfers depurinated DNA and RNA from agarose ... as 15 minutes ,Increases speed and efficiency ... be applied to gel ,Part of an ... and UV crosslinking in 2.5 hours, versus ...
Ice block will provide sufficient cooling for most normal blotting applications. Sealed block is held submerged in transfer buffer. Ice block will not spill during refreezing....
Medicine Products: